Background-Noninvasive detection of deep venous thrombi and subsequent pulmonary thromboembolism is a serious medical challenge, since both incidences are difficult to identify by conventional ultrasound techniques. Methods and Results-Here, we report a novel technique for the sensitive and specific identification of developing thrombi using background-free 19 F magnetic resonance imaging, together with α2-antiplasmin peptide (α2 AP )-targeted perfluorocarbon nanoemulsions (PFCs) as contrast agent, which is cross-linked to fibrin by active factor XIII. Ligand functionality was ensured by mild coupling conditions using the sterol-based postinsertion technique. Developing thrombi with a diameter <0.8 mm could be visualized unequivocally in the murine inferior vena cava as hot spots in vivo by simultaneous acquisition of anatomic matching 1 H and 19 F magnetic resonance images at 9.4 T with both excellent signal-to-noise and contrast-to-noise ratios (71±22 and 17±5, respectively). Furthermore, α2
T hrombosis plays a crucial role in a variety of cardiovascular diseases such as myocardial infarction, deep venous thrombosis, and pulmonary embolism, which are major causes of morbidity and mortality. More recently, it has been shown that patients with tumor have up to an 7-fold and obese people a 2.5-fold increased risk of developing thromboembolic events 1, 2 caused by systemically increased proinflammatory conditions and the release of prothrombotic factors. Thus, visualization and specific identification of thrombi by imaging techniques address an important clinical problem.
Clinical Perspective on p 1414
Thrombi can be visualized noninvasively by ultrasound, 3 computed tomography, 4 or magnetic resonance (MR) imaging (MRI). 5 MRI is free of ionizing radiation and has high spatial resolution in deep tissues that are not accessible by ultrasound. However, thrombus detection by conventional MRI 1 H MRI is difficult because small, nonocclusive thrombi have only a minor impact on blood flow and may not give rise to a clear signal in weighted images. To overcome this limitation, gadoliniumbased probes raised against fibrin within the thrombus have been developed (EP-2104R). [6] [7] [8] [9] [10] [11] Another specific marker of developing thrombi is factor XIIIa (FXIIIa), which cross-links α2-antiplasmin with fibrin during the early phase of thrombus formation. 12, 13 Probes based on α2-antiplasmin have been used for ex vivo or in vivo labeling of thrombi by near-infrared fluorescence, scintigraphy, or gadolinium-enhanced 1 H MRI. [14] [15] [16] [17] Recently, 19 F MRI has emerged as a promising novel technique for molecular imaging. For this, emulsified, biologically inert perfluorocarbons (perfluorocarbon nanoemulsions [PFCs] ) are used as a contrast agent to follow the fate of ex vivo or in vivo PFC-labeled cells. [18] [19] [20] Because 19 F is physiologically found in biological tissue in only trace amounts, the resulting fluorine signal displays an excellent degree of specificity. Merging of 19 F images with corresponding 1 H data sets enables the exact anatomic localization of the 19 F signal. Because 19 F MRI generates a positive contrast as a "hot spot," it is especially useful for heterogeneous tissue in which 1 H-based contrast is challenged by susceptibility artifacts or sparse proton density, complicating the interpretation of effects obtained by other contrast agents. Until now, 19 F MRI has been used predominantly for immune cell tracking in a variety of clinically relevant inflammation models. [21] [22] [23] [24] [25] [26] [27] [28] [29] This approach is based on the rapid uptake of intravenously injected PFCs by circulating monocytes that subsequently migrate into the inflamed area, resulting in a local accumulation of 19 F-loaded immune cells. In the present study, we report a novel procedure for the generation of targeted PFCs that makes use of a sterol-based postinsertion technique (SPIT) to generate α2-antiplasminlabeled PFCs (α2 AP -PFCs). SPIT allows modification of preformed PFCs under mild conditions that maintain the functionality of labile ligands. Using α2 AP -PFCs, we were able to detect the formation of developing deep venous thrombi and pulmonary embolism with 1 H/ 19 F MRI in vivo with a high specificity and sensitivity.
Methods
An expanded Methods section can be found in the online-only Data Supplement.
Perfluorocarbon Nanoemulsions
PFCs were prepared as previously reported (see the online-only Data Supplement for more details).
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Sterol-Based Postinsertion Technique
Generation of the Cholesterol-PEG 2000 -Maleimide Anchor
An equimolar mixture of maleimide-PEG 2000 -NH 2 (Jenkem Technology, Plano, TX), cholesteryl chloroformate (Sigma Aldrich, Seelze, Germany), and the activator triethylamine (Carl Roth, Karlsruhe, Germany) in water-free methylene chloride was prepared. The mixture was stirred for 24 hours under exclusion of light in a nitrogen atmosphere. The resulting cholesterol-PEG 2000 -maleimide was purified by chromatography with the use of a Sephadex LH-20 column and validated by 1 H nuclear magnetic resonance spectroscopy. Aliquots were stored at −80°C under argon.
Coupling of α2 AP to the Cholesterol-PEG Anchor
To generate PFCs for site-specific targeting of thrombi, we used a 14-amino acid peptide derived from α2 AP that is known to be crosslinked to fibrin at the glutamine Q3 by FXIIIa. [15] [16] [17] As control, Q3 was converted to alanine (Q3A), leading to a low-affinity substrate for FXIIIa. 17 Both peptides were further functionalized with a cysteine residue at amino acid position 13 ( Figure I in the online-only Data Supplement) for coupling to the cholesterol-PEG anchor. For immunofluorescence studies, carboxyfluorescein was linked via an additional lysine at the c-terminal tryptophan (W14).
All peptides (Genaxxon, Ulm, Germany) were dissolved in sterile phosphate buffer (10 mmol/L phosphate isotonized with glycerol, pH 7.4) to 5 mg/mL. The peptides were added to the cholesterol-PEG 2000 -maleimide anchor, and the mixture was shaken at 17°C for 20 hours at 700 rpm. The cholesterol anchor was used in 10-fold excess compared with the ligand, thus allowing a quantitative coupling of peptides. During the incubation period, the thiol group of the cysteine residue and the maleimide group form a stable thioether bond. 30 Free maleimide groups were subsequently deactivated by the addition of mercaptoethanolamine. This way, a mixture of cholesterol-PEG 2000 -peptide and deactivated cholesterol-PEG 2000 (approximate ratio of 1:10) was obtained and used in the following insertion step.
Postinsertion
Preformed PFCs were incubated with the obtained mixture on a rotary shaker at 17°C for 1 hour. As illustrated in Figure 1A , this leads to the spontaneous insertion of the cholesterol moiety into the phospholipid layer of the PFC 31 (molar ratio of phospholipid to cholesterol derivative, 20:1). PEGylated but nontargeted PFCs were formed by incubation with nonmodified cholesterol-PEG 2000 only.
Characterization of PFCs
The resulting emulsions were characterized by photon correlation spectroscopy on a Malvern Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany) to determine the hydrodynamic diameter, the polydispersity index, and the ζ potential. Compared with nonmodified PFCs, we observed a slight increase in size (diameter: nontargeted PFCs, 149±15 nm; α2 
Animal Experiments
Animal experiments were in accordance with institutional guidelines on animal care. Male mice (C57BL/6; body weight, 25-30 g; age, 8-10 weeks) used in this study were bred at the central animal facility of the Heinrich Heine University (Düsseldorf, Germany). They were fed a standard chow diet and received tap water ad libidum.
Induction of Venous Thrombi and Pulmonary Thromboembolism
During surgery, mice were kept under anesthesia with 1.5% isoflurane. Buprenorphin was injected for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomic level of both kidneys. Subsequently, a filter paper (1×4 mm 2 ) soaked with 10% FeCl 3 was placed on top of the vessel and incubated for 8 minutes. To ensure the location of the FeCl 3 -soaked filter paper on top of the vessel surface, 2 stretches of parafilm were placed on both sides of the vessel. After removal of the filter paper, the vessel was washed with 0.9% NaCl to remove residual by guest on July 25, 2017 http://circ.ahajournals.org/ Downloaded from FeCl 3 . PFCs (3 mmol/kg body weight) were injected into the tail vein ≈5 minutes before thrombus induction or 5, 15, 30, 60, or 90 minutes after thrombus induction. Subsequently, MRI scans were performed at 2, 8, or 24 hours after surgery. To induce pulmonary thromboembolism, a mixture of human thrombin (Sigma-Aldrich, Seelze, Germany; 10 U/25 g body weight) and α2 AP -PFCs (or unmodified PFCs/Q3A-PFCs as control) was injected that resulted in an 80% survival rate.
1 H/ 19 F MRI measurements were performed 24 hours later.
MRI Studies
Experiments were performed with a vertical 9.4-T Bruker AVANCE III Wide Bore nuclear magnetic resonance spectrometer (Bruker, Rheinstetten, Germany) operating at frequencies of 400.21 MHz for 1 H and 376.54 MHz for 19 F measurements using microimaging units as described previously. [22] [23] [24] [25] 27, 32 Mice were anaesthetized with 1.5% isoflurane and were kept at 37°C during the measurements. Data were acquired with the use of a 25-mm birdcage resonator tunable to 1 H and 19 F. After acquisition of the morphological 1 H images, the resonator was tuned to 19 F, and anatomically matching 19 F images were recorded (see the online-only Data Supplement for a more detailed description of MRI setup, acquisition parameters, and quantification procedures). An overview over all imaging parameters used for 1 H/ 19 F MRI is given in Table I in the online-only Data Supplement.
In Vitro Thrombus Studies
Human blood was obtained by venous puncture and collected on ice. Blood (100 μL) was transferred to a round-bottom 96-well plate and incubated at 37°C for 15 minutes. Next, 25 μL PFCs (nontargeted PFCs or α2 AP -PFCs) were added to each well, and the plate was further incubated for 90 minutes at 37°C under constant motion. The blood clots were extensively washed with cold PBS and subjected to 1 H/ 19 F MRI. Details about PFC uptake studies by murine blood are given in the expanded Method section of the online-only Data Supplement.
Cytotoxicity Assay
Murine splenocytes were obtained from C56BL/6 mice, incubated with the different PFCs, and analyzed as described in the expanded Method section of the online-only Data Supplement.
Flow Cytometry
Mice were killed by cervical dislocation, and thrombi were excised and digested in streptokinase/plasmin (150/2 U/mL) for 30 minutes at 37°C under constant shaking. To generate a single-cell suspension, thrombi were passed through a 70-μm cell strainer (BD Biosciences, Heidelberg, Germany), washed with fluorescenceactivated cell sorter buffer, and stained for 30 minutes with fluorochrome-coupled antibodies as described in the online-only Data Supplement.
Histology and Fluorescence Microscopy
Excised thrombi and lungs were fixed in 4% paraformaldehyde or embedded in Tissue-Tek (Weckert Labortechnik, Kitzingen, Germany) and frozen at −20°C. Sections of 8 or 14 μm were cut and processed for immunohistochemical staining as described previously 23, 24, 32 (see the online-only Data Supplement for more details).
Statistics
All data were evaluated for normal distribution with the Shapiro-Wilk test and are given as mean±SD. Statistical difference was assessed 
MRI In Vivo
To generate PFCs for the targeting of developing thrombi, we used a 14-amino acid peptide derived from α2 AP ( Figure I in the online-only Data Supplement), which is cross-linked by FXIIIa to fibrin at the glutamine Q3 during the early phase of the thrombus development. [15] [16] [17] As control, we applied an FXIIIa low-affinity peptide in which glutamine was replaced by alanine in position 3 (Q3A). 15, 16 Both peptides were coupled to cholesterol-PEG-maleimide and inserted into preformed PFCs by SPIT ( Figure 1A) .
To explore the suitability of α2 Figure 1B , animals that received α2 AP -PFCs display a strong background-free 19 F signal at the site of the newly formed thrombus that can be dimly recognized in 1 H MRI at the ventral side of the vena cava as a dark gray structure (arrows in Figure 1B , bottom). Although α2 AP -PFCs clearly delineated the thrombus, no signal was found in the area surrounding the surgery ( Figure 1B, top) , indicating the specificity of labeling. 19 F signals were found to be substantially reduced when PFCs with Q3A-control peptide were used ( Figure 1B, bottom) . Quantification of all data revealed a strongly enhanced 19 F signal for α2 AP -PFCs compared with control Q3A-PFCs (P<0.05; Figure 1B , right). Note that the mean diameter of the thrombi was <1 mm (0.74±0.16 mm; n=8) and that mere angiographic MR 1 H scans did not permit us to precisely detect the location of the thrombus because only minor alterations in the blood flow were observed ( Figure IIIA in the online-only Data Supplement). Although thrombi could be detected in high-resolution spin-echo MRIs, the calculated contrast-to-noise ratio for 1 H and 19 F signals between thrombus and the adjacent vessel lumen, muscle, and connective AP -PFCs were injected 60 minutes after thrombus induction, whereas after 90 minutes, PFC deposition was not detected any longer. In separate in vivo experiments with untreated animals, we determined the 19 F signal in the blood by MRI ( 19 F FLASH) and found that the blood halflife of peptide-targeted PFCs was ≈2 hours ( Figure 2B , blue circles). A similar half-life was found for PEGylated PFCs without peptide ( Figure 2C , left), indicating that the PEGylation but not the peptide determines the kinetics within the circulation ( Figure 2C , right). Interestingly, unmodified non-PEGylated PFCs remained in the bloodstream for a much longer time, with a half-life of ≈20 hours ( Figure 2C ).
To further corroborate the location of the 19 F signal within the thrombus, excised tissue samples were analyzed ex vivo by histology and by high-resolution 1 H/ 19 F MRI. Hematoxylin and eosin and Sirius Red staining confirmed thrombus formation, with the presence of trapped erythrocytes as a hallmark of deep venous thrombi ( Figure 3A ). Ex vivo MRI identified the thrombus as structure with inhomogeneous contrast surrounded by the dark vessel lumen and the embedding agarose (dark gray, Figure 3B ; left, longitudinal sections; right, axial sections). Detected 19 F signal was clearly restricted to the thrombus and exhibited a patchy pattern distributed over the entire thrombus. This result was confirmed by histology through the use of PFCs with carboxyfluorescein-labeled α2 AP -peptide, which also showed a patchy distribution of the fluorescence signal within the thrombus ( Figure 3C , top). No signal could be observed in control thrombi from animals that received Q3A-carboxyfluorescein-PFCs ( Figure 3C , bottom).
Specificity of α2
AP -PFCs for Developing Thrombi
Trapping of PFC-loaded monocytes or PFCs themselves might have contributed to the observed 19 F signal in the thrombus. Therefore, we explored whether unmodified PFCs or PEGylated PFCs without peptide enrich in venous thrombi. As shown in Figure 4A , intravenous administration of PFCs or PEG-PFCs before thrombus induction did not lead to the deposition of any 19 F signal within thrombi (white arrows, Figure 4A ). Flow cytometry on the cellular composition of thrombi revealed a small amount of CD45 + /CD11b + immune cells ( Figure 4B , left and middle) that consist predominantly of neutrophils and a negligible number of monocytes ( Figure 4B , right). Interestingly, unmodified PFCs, which are known to be avidly taken up by macrophages, 22, 23 gave rise to a strong 19 F signal in the inflamed area of surgery ( Figure 4A , top, yellow arrows). In contrast, PEGylated PFCs did not accumulate in inflamed areas ( Figure 4A , bottom). This phenomenon is most likely attributable to an impaired uptake of PEGylated PFCs by monocytes under these conditions. This assumption was confirmed by separate experiments, where the uptake of PEGylated PFCs by blood monocytes and RAW macrophages was found to be strongly reduced compared with neat 
Detection of Pulmonary Thromboembolism
Venous thrombi are strongly prone to cause pulmonary thromboembolism. We therefore explored whether 19 F MRI is also suitable for the detection of thrombi accumulating in the lung. To this end, we injected human thrombin, known to elicit 19 F signals can also be observed in the liver, which is known to be a major site of PFC accumulation. 34 The specificity of the 19 F signals was validated in separate experiments in which thrombin was injected in combination with untargeted PFCs or Q3A-PFCs. Under these conditions we found no 19 F signals in the lung ( Figure V in the online-only Data Supplement). In addition, we performed ex vivo MR analyses and found 19 F signals in all animals that received thrombin plus α2 AP -PFCs but not in control animals (thrombin plus neat PFCs; thrombin plus Q3A-PFCs).
Figure 5B displays corresponding postmortem high-resolution MRI scans of the excised lung of the same animal shown in Figure 5A , which confirms the location of the 19 F signal within the right lobe of the lung (Figure 5B, left) . Interestingly, 3-dimensional reconstruction of the data sets also revealed weaker signals 
Labeling of Human Thrombi With α2
AP -PFCs
To test whether α2 AP bound to PFCs can also label human thrombi, human thrombi generated in vitro were treated with untargeted PFCs or α2 AP -PFCs during the early phase of thrombus formation. As shown in Figure 6A , we observed a 10-fold-increased 19 F signal for α2 
Discussion
In the present study, we report a novel technique for the noninvasive detection of thrombi and pulmonary embolism that is based on 19 F MRI combined with α2 AP -targeted PFCs. With the use of SPIT, targeting ligands were attached to preformed PFCs under mild conditions that maintained their integrity. This approach proved to be suitable for the detection of developing thrombi with a diameter of <1 mm in a reasonable scan time (30 minutes) and with high sensitivity (signal-to-noise ratio, 70). Specificity is further provided by the rapid clearance of α2 AP -PFCs from the bloodstream by liver and spleen. In addition, uptake of α2 AP -PFCs by blood monocytes is strongly impaired compared with unmodified PFCs, resulting in the absence of PFC accumulation in inflamed areas and therefore in a strongly reduced background signal.
Ultrasound is the gold standard for the diagnosis of deep venous thrombi of legs but is not suitable for structures located more deeply (eg, lung). This translates to a local PFC concentration of ≈40 mmol/L, which is substantially higher than reported for EP-2104R (<0.25 mmol/L).
9,35-39 However, there are several future options to optimize our present approach: Enhanced sensitivity can be obtained by increased voxel size or by improvements in hardware and imaging sequences. Zhong et al 40 recently achieved an 8-fold decrease in scan time by implementing compressed sensing for 19 F MRI, which could alternatively be used for lowering the PFC doses. On the other hand, given the high signalto-noise ratio observed in this study, the applied dose of the contrast agent could be reduced several-fold in either case.
Generation of targeted PFCs with labile ligands is generally hampered by the manufacturing process, which usually requires high pressure to obtain stable nanoemulsions with a narrow size distribution, 31 High-pressure homogenization causes substantial shear forces and cavitation; the latter generates local heat of up to 10 4 K by implosion of dispersant gas bubbles resulting from low static pressure. 41 Obviously, such conditions are disadvantageous for the handling of sensitive ligands such as peptides, antibodies, or antibody fragments. This might explain the low signal-to-noise ratios of recent approaches for in vivo 19 F MRI using targeted PFCs in a tumor model and after lung ischemia.
42,43 SPIT, used here to modify preformed PFCs, overcomes the problem of possible ligand destruction when linked before high-pressure homogenization. Insertion of the targeting ligand by SPIT can be performed at room temperature with gentle agitation. Furthermore, SPIT-targeted PFCs can be produced in very small quantities down to ≤100 μL, which cannot be handled by conventional methods because homogenizers for such small volumes are not available. Importantly, this technique makes use of cholesterol-PEG, which is well tolerated by organism and cells ( Figure IIC in the online-only Data Supplement). In addition, SPIT is not restricted to peptides and antibodies but also works with different reactive groups and ligands such as single-chain monoclonal antibodies or small proteins.
So far, 19 F MRI has been widely used for immune cell tracking because of the efficient uptake of unmodified PFCs by blood monocytes after intravenous injection. [21] [22] [23] [24] [25] 27, 29, 32, 34 Tracking of blood cells without phagocytic properties (such as T cells) or distinct cell types (dendritic cells, monocyte or macrophage subsets) previously required ex vivo labeling with PFCs and reimplantation. [44] [45] [46] However, attachment of specific ligands for distinct surface epitopes to PFCs by the postinsertion technique should enable the direct in vivo labeling of target cells after intravenous injection in future studies.
MRI offers excellent spatial resolution, and the sensitivity of α2 AP -PFCs should be suitable to detect newly formed small thrombi that only partially affect the blood flow in thromboembolic lungs or deep veins in a clinically relevant situation. Specific assessment of early thrombus formation versus organized thrombi will improve the selection of patients who benefit from fibrinolytic therapy and will help to adequately adjust doses in lysis schemata, thereby reducing serious side effects such as bleeding in situations when chronic thrombi are resistant to fibrinolytic therapy. In vivo imaging of FXIIIa activity via α2 AP -PFCs could further aid in monitoring of imminent thrombus formation after implantation of such devices as pacemakers, valves, or scaffolds and in identifying latent thrombus generation in structures characterized by low blood flow velocities and prone to stasis such as the left atrial appendage. Besides coupling α2-antiplasmin peptide, SPIT holds the potential to be adapted for single-chain monoclonal antibodies raised against activated glycoprotein IIb/IIIa 47 or peptides that bind to existing thrombi, 10 also enabling the assessment of persistent thrombi by 19 F MRI. The method described here has significant translational potential. Similar to mice, α2 AP -targeted PFCs also specifically bind to human thrombi ( Figure 6 ) owing to the speciesindependent cross-linking of α2-antiplasmin with FXIIIa. 48 Specific targeting, in combination with PEGylation, also ensures that the nanoparticle uptake by monocytes is strongly reduced. Furthermore, perfluorocarbons are biochemically inert as a result of the strong C-F bond, which cannot be cleaved by enzymes, and are therefore nontoxic. 49 Human application of SPIT is feasible with the use of the clinically relevant perfluorooctyl bromide and perfluorodecalin emulsions, which are characterized by short biological half-lives 34 and have been used in human trials. Because of the excellent sensitivity and specificity, we propose that α2 AP -PFCs, in conjunction with 19 
CLINICAL PERSPECTIVE
The formation of fibrin-rich deep venous thrombi has a high incidence in the elderly, obese people, and, especially, in patients with tumors, strongly affecting morbidity and mortality. For specific visualization of newly formed thrombi, we used α2-antiplasmin peptide-labeled perfluorocarbon nanoemulsions as the contrast agent, which is cross-linked by factor XIIIa to the developing fibrin network. By simultaneous acquisition of matching anatomic proton ( 1 H) and fluorine ( 19 F) magnetic resonance images, this approach can precisely locate newly formed thrombi as "hot spots."
19 F magnetic resonance imaging is a background-free imaging approach that provides robust signals with an excellent degree of specificity, allowing an imaging scenario in the clinical setting as follows: Without prior knowledge of the thrombus location, a fast, low-resolution, wholebody 19 F magnetic resonance imaging scan could be carried out. After identification of 1 or more 19 F hot spots, additional high-resolution 1 H and 19 F scans could be recorded solely at these predefined regions for unambiguous anatomic localization of the developed thrombi. The specific assessment of early thrombus formation versus organized thrombi can improve the selection of patients who benefit from fibrinolytic therapy and help to adjust doses in lysis schemata, reducing serious side effects when chronic thrombi are resistant to therapy. In vivo imaging of factor XIIIa activity via α2-antiplasmin peptidelabeled perfluorocarbon nanoemulsions could further aid in monitoring of imminent thrombus formation after implantation of devices such as pacemakers, valves, or scaffolds and in identifying latent thrombus generation in structures characterized by low blood flow velocities and prone to stasis such as the left atrial appendage.
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SUPPLEMENTAL MATERIAL EXPANDED METHODS
Perfluorocarbon nanoemulsions
Formation: Perfluorocarbon nanoemulsions (PFCs) were prepared as previously reported 1, 2 .
In brief, 2.4% (w/w) phospholipid (Lipoid S75, Lipoid AG, Ludwigshafen, Germany) was dispersed in 10 mM phosphate buffer (isotonized with glycerol), 20% (w/w) perfluoro-15-crown-5 ether (ABCR, Karlsruhe, Germany) was added to the dispersion and a crude emulsion was formed by high shear mixing (Ultra Turrax TP 18/10; IKA-Werke, Staufen, Germany). High pressure homogenization was performed in 10 cycles at 1000 bar (Avestin Emulsiflex C5, AVESTIN Europe, Mannheim, Germany). PFCs were heat-sterilized in glass vials under standard conditions (121 °C, 2 bar, 20 min.). Average particle size was determined by photon correlation spectroscopy to be 149±15 nm. Rhodamine-labelled PFCs were prepared as described previously 1, 2 . Equal intensities of the fluorescence signal for different rhodamine-labelled emulsions were confirmed by an IVIS spectrometer (Perkin Elmer, Rodgau, Germany, see supplemental Fig. S2A ). Aliquots were stored at -80 °C under argon.
Coupling of α2-antiplasmin peptide to the cholesterol-PEG anchor: To generate PFCs for site specific targeting of thrombi by 19 F MRI, we used a 14 amino acid peptide derived from α2-antiplasmin (α2 AP ) which is known to be cross-linked to fibrin at the glutamine Q3 by factor XIIIa [3] [4] [5] . As control, Q3 was converted to alanine (Q3A) leading to a low affinity substrate for FXIIIa 5 . Both peptides were further functionalized with a cysteine residue at amino acid position 13 (supplemental Fig. S1 ) for coupling to the cholesterol-PEG anchor.
For immunofluorescence studies, carboxyfluorescein (CF) was linked via an additional lysine at the c-terminal tryptophan (W14).
All peptides (Genaxxon, Ulm, Germany) were dissolved in sterile phosphate buffer (10 mM 
Characterization of PFCs
The resulting emulsions were characterized by photon correlation spectroscopy (PCS) on a Malvern Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany) to determine the hydrodynamic diameter, the polydispersity index (PDI) and the ζ-potential. In comparison to non-modified PFCs, we observed a slight increase in size (diameter: non-targeted PFCs = 149±15 nm; α2 
Animal experiments
Animal experiments were approved by the "Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen" and were performed in accordance with the national guidelines on animal care. Male mice (C57BL/6; 25-30 g body weight; 8-10 weeks of age) used in this study were bred at the central animal facility of the Heinrich Heine University (Düsseldorf, Germany) and fed with a standard chow diet and received tap water ad libidum.
Induction of venous thrombi and pulmonary thromboembolism
During surgery, mice were kept under anaesthesia with 1.5% isoflurane. Buprenorphin was injected for analgesia. A median laparotomy was performed, and the inferior vena cava was exposed at the anatomical level of both kidneys. Subsequently, a filter paper (1´4 mm 
MRI studies
Experiments were performed at a vertical 9.4 T Bruker AVANCE F measurements using microimaging units as described previously 1, 2, [8] [9] [10] [11] . Mice were anaesthetized with 1.5% isoflurane and were kept at 37 °C during the measurements. Data were acquired using a 25-mm birdcage resonator tuneable to Table 1 . 
In vitro thrombus generation and PFC uptake
Flow cytometry
Mice were killed by cervical dislocation thrombi were excised and digested in streptokinase/plasmin (150 U/ml and 2 U/ml) for 30 min at 37 °C under constant shaking. To generate a single cell suspension, thrombi were passed through a 70 µm cell strainer (BD Biosciences, Heidelberg, Germany), washed with FACS buffer (PBS, 5% BSA, 0.5 mM EDTA and 0.1% NaN 3 ) and stained for 30 min with fluorochrome-coupled antibodies: CD45 (PE; 3F11.1), CD11b (APC; M1/70), CD3 (APC; 145-2c11) (all Miltenyi Biotec, Bergisch Gladbach, Germany, Ly6G (FITC; 1A8; BD-Pharmingen, Heidelberg, Germany), B220 (APC.Cy7; RA3 6B2) and CD41 (PE-Cy.7; MWReg30) (both: eBiosciences, San Diego, CA).
Histology and fluorescence microscopy
Excised thrombi and lungs were fixed in 4% PFA or embedded in Tissue-Tek (Weckert Labortechnik, Kitzingen, Germany) and frozen at -20 °C. Sections of 8 µm or 14 µm were cut and processed for immunohistochemical staining as described previously 2, 8, 11 . In brief, thrombus sections were fixed in Zamboni´s fixation for 10 min and then incubated with 
